Dr. Reddy’s Laboratories Ltd ADR Total Liabilities
Dr. Reddy’s Laboratories Ltd ADR total liabilities. Based on the latest financial reports, Dr. Reddy’s Laboratories Ltd ADR (RDY) has total liabilities worth $187.14 Billion USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check RDY asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Dr. Reddy’s Laboratories Ltd ADR (2000–2025)
Total liabilities of Dr. Reddy’s Laboratories Ltd ADR from 2000 to 2025. This chart illustrates how Dr. Reddy’s Laboratories Ltd ADR's total liabilities have evolved over time, based on quarterly financial data. Explore RDY strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Dr. Reddy’s Laboratories Ltd ADR Competitors by Total Liabilities
The table below lists competitors of Dr. Reddy’s Laboratories Ltd ADR ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Eurofins Scientific SE
F:ESF0
|
Germany | €6.41 Billion |
|
ZTO Express (Cayman) Inc
NYSE:ZTO
|
USA | $34.90 Billion |
|
Deckers Outdoor Corporation
NYSE:DECK
|
USA | $1.57 Billion |
|
Zebra Technologies Corporation
NASDAQ:ZBRA
|
USA | $4.86 Billion |
|
TELECOM ITALIA ADR 1
F:TQIA
|
Germany | €22.95 Billion |
|
Pinnacle West Capital Corp
NYSE:PNW
|
USA | $22.68 Billion |
|
Smurfit Kappa Group PLC
F:SK3
|
Germany | €27.09 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Dr. Reddy’s Laboratories Ltd ADR's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see RDY current and non-current assets.
Liquidity & Leverage Metrics
Dr. Reddy’s Laboratories Ltd ADR Total Liabilities Ratios Explained
Dr. Reddy’s Laboratories Ltd ADR total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.88 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.33 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Dr. Reddy’s Laboratories Ltd ADR's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Dr. Reddy’s Laboratories Ltd ADR (2000–2025)
The table below shows the annual total liabilities of Dr. Reddy’s Laboratories Ltd ADR from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | $155.82 Billion | +45.67% |
| 2024-03-31 | $106.97 Billion | +17.72% |
| 2023-03-31 | $90.86 Billion | -11.18% |
| 2022-03-31 | $102.30 Billion | +7992.20% |
| 2021-03-31 | $1.26 Billion | +23.80% |
| 2020-03-31 | $1.02 Billion | -98.80% |
| 2019-03-31 | $85.23 Billion | -14.03% |
| 2018-03-31 | $99.14 Billion | +3.52% |
| 2017-03-31 | $95.78 Billion | +20.76% |
| 2016-03-31 | $79.31 Billion | -4.97% |
| 2015-03-31 | $83.46 Billion | +5.08% |
| 2014-03-31 | $79.42 Billion | -88.53% |
| 2013-03-31 | $692.64 Billion | +1016.58% |
| 2012-03-31 | $62.03 Billion | +26.56% |
| 2011-03-31 | $49.02 Billion | +31.00% |
| 2010-03-31 | $37.41 Billion | -10.38% |
| 2009-03-31 | $41.75 Billion | +8.78% |
| 2008-03-31 | $38.38 Billion | -13.63% |
| 2007-03-31 | $44.44 Billion | -4.43% |
| 2006-03-31 | $46.50 Billion | +457.83% |
| 2005-03-31 | $8.34 Billion | +49.05% |
| 2004-03-31 | $5.59 Billion | +31.65% |
| 2003-03-31 | $4.25 Billion | +21.16% |
| 2002-03-31 | $3.51 Billion | -46.90% |
| 2001-03-31 | $6.60 Billion | +11753.42% |
| 2000-03-31 | $55.70 Million | -- |
About Dr. Reddy’s Laboratories Ltd ADR
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more